Targeting HSF1 for cancer treatment: mechanisms and inhibitor development

Chin, Yeh; Gumilar, Khanisyah E; Li, Xing-Guo; Tjokroprawiro, Brahmana A.; Lu, Chien-Hsing; Lu, Jianrong; Zhou, Ming; Sobol, Robert W.; Tan, Ming

doi:10.7150/thno.82431



Nanotheranostics 2024; 8(3): 380-400. [Abstract] [Full text] [PDF]

Nanotheranostics 2024; 8(3): 344-379. [Abstract] [Full text] [PDF] [PubMed] [PMC]

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

Global reach, higher impact

Full Text | PDF

Theranostics 2023; 13(7):2281-2300. doi:10.7150/thno.82431 This issue Cite

Review

Targeting HSF1 for cancer treatment: mechanisms and inhibitor development

Yeh Chin^1*, Khanisyah E Gumilar^1,2*, Xing-Guo Li^1,7, Brahmana A. Tjokroprawiro², Chien-Hsing Lu³, Jianrong Lu⁴, Ming Zhou⁵, Robert W. Sobol⁶, Ming Tan^1,7✉

1. Graduate Institute of Biomedical Sciences and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan, R.O.C.
2. The Department of Obstetrics and Gynecology, Medical Faculty, Universitas Airlangga, Surabaya, Indonesia.
3. Department of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
4. Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, USA.
5. Cancer Research Institute and School of Basic Medical Sciences, Central South University, Changsha, China.
6. Department of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, USA.
7. Institute of Biochemistry & Molecular Biology, China Medical University, Taichung, Taiwan, R.O.C.
*These authors contributed equally to this work.

Citation:

Chin Y, Gumilar KE, Li XG, Tjokroprawiro BA, Lu CH, Lu J, Zhou M, Sobol RW, Tan M. Targeting HSF1 for cancer treatment: mechanisms and inhibitor development. Theranostics 2023; 13(7):2281-2300. doi:10.7150/thno.82431. https://www.thno.org/v13p2281.htm

Other styles

Abstract

Heat Shock Factor 1 (HSF1) is a master regulator of heat shock responsive signaling. In addition to playing critical roles in cellular heat shock response, emerging evidence suggests that HSF1 also regulates a non-heat shock responsive transcriptional network to handle metabolic, chemical, and genetic stress. The function of HSF1 in cellular transformation and cancer development has been extensively studied in recent years. Due to important roles for HSF1 for coping with various stressful cellular states, research on HSF1 has been very active. New functions and molecular mechanisms underlying these functions have been continuously discovered, providing new targets for novel cancer treatment strategies. In this article, we review the essential roles and mechanisms of HSF1 action in cancer cells, focusing more on recently discovered functions and their underlying mechanisms to reflect the new advances in cancer biology. In addition, we emphasize new advances with regard to HSF1 inhibitors for cancer drug development.

Keywords: HSF1, Heat shock response, cellular stress, cancer

Citation styles

APA

Chin, Y., Gumilar, K.E., Li, X.G., Tjokroprawiro, B.A., Lu, C.H., Lu, J., Zhou, M., Sobol, R.W., Tan, M. (2023). Targeting HSF1 for cancer treatment: mechanisms and inhibitor development. Theranostics, 13(7), 2281-2300. https://doi.org/10.7150/thno.82431.

ACS

Chin, Y.; Gumilar, K.E.; Li, X.G.; Tjokroprawiro, B.A.; Lu, C.H.; Lu, J.; Zhou, M.; Sobol, R.W.; Tan, M. Targeting HSF1 for cancer treatment: mechanisms and inhibitor development. Theranostics 2023, 13 (7), 2281-2300. DOI: 10.7150/thno.82431.

NLM

CSE

Chin Y, Gumilar KE, Li XG, Tjokroprawiro BA, Lu CH, Lu J, Zhou M, Sobol RW, Tan M. 2023. Targeting HSF1 for cancer treatment: mechanisms and inhibitor development. Theranostics. 13(7):2281-2300.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.